10-K: Longevity Health Holdings Reports 2024 Results, Focuses on Bio-Aesthetics and Navigates Financial Challenges

Longevity Health Holdings, Inc. reports its 2024 financial results, highlighting a strategic shift towards bio-aesthetics and addressing concerns about its ability to continue as a going concern.

Summary

• Longevity Health Holdings, Inc. released its Form 10-K for the fiscal year ended December 31, 2024.
• The company is focusing on longevity and healthy aging, with a shift towards regenerative bio-aesthetics.
• They currently market two cosmetic product lines, Carmell Secretome TM and Elevai Exosomes TM, aimed at skin and hair health.
• The company has paused further research and development on innovative regenerative bone and tissue healing products.
• Recent developments include a private placement on January 2, 2025, which generated gross proceeds of $1,851,849.
• The company completed the Elevai Acquisition on January 16, 2025, acquiring the cosmetic skincare and haircare business of PMGC Holdings, Inc.
• Elevai had net sales of approximately $2,500,000 for the year ended December 31, 2024.
• The company changed its name from Carmell Corporation to Longevity Health Holdings, Inc. on March 6, 2025.
• The company received delisting notices from Nasdaq due to not meeting minimum bid price and market value requirements.
• As of December 31, 2024, the company had negative net working capital of $4,921,151 and a net loss from continuing operations of $10,650,464.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The company is involved in litigation with the Holders of Convertible Notes, who allege additional payments are owed.
• Gross sales for the year ended December 31, 2024, were $90,829 from sales of cosmetic skincare products.
• Research and development expenses decreased by $1,442,908 to $1,054,310 for the year ended December 31, 2024, due to a strategic realignment.
• The company had a loss from discontinued operations of $1,152,276 for the year ended December 31, 2024, related to the AxoBio business.
• The company recognized a non-cash gain on the sale of AxoBio of $1,434,479 for the year ended December 31, 2024.
• The company is exploring out-licensing certain research and development programs to enhance liquidity.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive developments like the Elevai acquisition and a private placement, the company faces significant financial challenges, including going concern doubts and Nasdaq delisting notices. The overall sentiment is cautiously negative.

Positives

• The company is focusing on longevity and healthy aging, with a shift towards regenerative bio-aesthetics.
• The company completed the Elevai Acquisition, adding a product line with approximately $2.5 million in net sales for 2024.
• A private placement on January 2, 2025, generated gross proceeds of $1,851,849.
• The company is exploring out-licensing certain research and development programs to enhance liquidity.
• Research and development expenses decreased by $1,442,908 to $1,054,310 for the year ended December 31, 2024, due to a strategic realignment.
• The company recognized a non-cash gain on the sale of AxoBio of $1,434,479 for the year ended December 31, 2024.

Negatives

• The company is facing Nasdaq delisting notices due to not meeting minimum bid price and market value requirements.
• There is substantial doubt about the company's ability to continue as a going concern, with negative net working capital of $4,921,151 and a net loss from continuing operations of $10,650,464 in 2024.
• The company is involved in litigation with the Holders of Convertible Notes.

Risks

• Limited experience as a commercial company may hinder the marketing and sale of cosmetic products.
• Failure to retain or recruit necessary personnel could impede development objectives.
• Reliance on third parties for raw materials, manufacturing, and packaging poses supply chain risks.
• Inability to manage inventory effectively could adversely affect results of operations.
• The company will need substantial additional funding, and failure to raise capital could force delays or elimination of product development programs.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The company may become involved in litigation that may materially adversely affect it.
• An economic downturn may harm the business and results of operations.
• Significant disruptions of information technology systems, computer system failures, or breaches of information security could adversely affect the business.
• The company will need to grow the size of its organization in the future, and it may experience difficulties in managing this growth.
• If the company were to be delisted from Nasdaq, it could reduce the visibility, liquidity, and price of its Common Stock.
• The price of the company's Common Stock may be volatile and may fluctuate substantially.

Future Outlook

The company expects to launch additional skincare products throughout 2025 and grow revenue from the Elevai product line. Management anticipates that revenue from the continued commercialization of its cosmetic products and the anticipated cost savings from the restructuring activities will assist the company in extending its cash runway. The company is also exploring raising additional capital and the out-licensing of certain research and development programs to enhance its liquidity.

Management Comments

• Management estimates that the company will need to raise additional capital to cover operating and capital requirements.
• Management believes that its obligations under the Convertible Notes and Convertible Note Warrants have been satisfied and that no additional payments are due to the Holders.

Industry Context

The skincare and haircare markets were approximately $280 billion in 2022 and are expected to grow at a 6.4% compound annual growth rate (CAGR). The aesthetics market is growing 36% faster than pharmaceuticals, according to Statista. The beauty industry is relatively concentrated, with a significant portion of retail sales in the United States generated by brands owned by a few large multinational companies, such as LOral, Este Lauder, Coty, Revlon, Shiseido, Johnson & Johnson, and Procter & Gamble.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To assess the results in the context of global benchmarks, specific comparable companies, projects, and results would need to be identified and analyzed.
• Without specific financial details from competitors like LOral, Este Lauder, or other smaller independent companies, a direct comparison is not possible.

Management Changes

Legal Proceedings

• Puritan Partners LLC filed a complaint against the company alleging breach of obligations under Convertible Notes and Convertible Note Warrants.

Related Party Transactions

• The company engaged a placement agent, of which a Board member is a managing partner, for the 2024 and 2025 Private Placements.
• The company's Chief Executive Officer invested $25,000 in the 2024 Private Placement.
• Entities affiliated with a partnership in which a Board member is a general partner purchased $50,000 of the 2023 Promissory Notes.
• AxoBio used OrthoEx for 3PL services, in which the former Chief Executive Officer of AxoBio has an equity interest and a seat on OrthoExs Board of Directors.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and the risk of delisting from Nasdaq.
• Employees face uncertainty due to the company's financial challenges and potential restructuring.
• Customers may be affected by changes in product development and availability.
• Suppliers and creditors face increased risk due to the company's going concern doubts.

Next Steps

• The company will continue to commercialize its cosmetic products.
• The company will pursue a hearing with the Nasdaq Hearings Panel to appeal the delisting determination.
• The company will explore raising additional capital and out-licensing certain research and development programs.
• The company will defend itself vigorously against the litigation filed by Puritan.

Key Dates

Keywords

Longevity Health Holdings, bio-aesthetics, cosmetic skincare, haircare, financial results, risk factors, Elevai, Carmell, private placement, acquisition